Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Isofol Medical AB ( (SE:ISOFOL) ).
Isofol Medical AB has commenced a clinical phase Ib/II study of its drug candidate arfolitixorin, intended as a new treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, will assess the benefit/risk profile of escalating doses and compare efficacy parameters, marking a significant step towards market readiness and potentially offering improved treatment options for patients with advanced cancers.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company’s primary drug candidate, arfolitixorin, aims to enhance the efficacy of first-line standard treatments for various solid tumors, with current studies targeting colorectal cancer, the third most common cancer globally.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
Find detailed analytics on ISOFOL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue